Home
Pain Therapeutics

Analgesics are among the most commonly prescribed drugs in the world and yet, finding novel targets and mechanisms that may elevate hard to treat pain is becoming more difficult.
After nearly 20 years of successful Pain Therapeutics conferences, join us for the 18th Annual Pain Therapeutics conference in May to explore novel targets for pain therapeutics, new translational approaches and pipeline drug development from the leading pharma companies in pain management.

 

With more case studies, improved networking opportunities and presentations on exciting cutting edge research, the 18th Annual Pain Therapeutics conference will equip you with the latest knowledge to advance your research and trials.

Exclusive content from industry leaders - follow Download Centre tab to view insightful interviews with Lotus Clinical Research and Centrexion Therapeutics

FEATURED SPEAKERS

Becca Senter

Becca Senter

Principal Scientist, Pharmacology, Flexion Therapeutics
Daniel Mikol

Daniel Mikol

Executive Medicl Director Global Development Neuroscience, Amgen
Iain Chessell

Iain Chessell

VP & Head, IMED Neuroscience , AstraZeneca
Kerrie Brady

Kerrie Brady

Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
Randall Stevens

Randall Stevens

Chief Medical Officer, Centrexion Therapeutics Corp.
William Schmidt

William Schmidt

Vice President, Clinical Development , ViroMed

Becca Senter

Principal Scientist, Pharmacology, Flexion Therapeutics
Becca Senter

Becca Senter is a Principal Scientist, Pharmacology in Non-Clinical Research at Flexion Therapeutics. Becca received her PhD in pharmacology in 2015 from Vanderbilt University from the laboratory of Dr. P. Jeffrey Conn. Working within the Vanderbilt Center for Neuroscience Drug Discovery, her research focused on understanding the roles of metabotropic glutamate receptors in neurodevelopmental diseases. She performed her postdoctoral studies at Massachusetts Institute of Technology in the laboratory of Dr. Mark Bear studying the development of drug tolerance in Fragile X syndrome. Becca joined Flexion Therapeutics in the winter of 2016 and is responsible for early stage development programs for the treatment of musculoskeletal disorders.

Daniel Mikol

Executive Medicl Director Global Development Neuroscience, Amgen
Daniel Mikol

Daniel Mikol obtained his MD and PhD at the University of Chicago under Kari Stefansson, now deCODE CEO. He completed a Neurology residency at the University of California, San Francisco and fellowship at the University of Michigan. He continued to work on staff at the University of Michigan, an active clinician and clinical researcher, with interests in neuroimmunology. He left the University of Michigan in 2008 as Associate Professor, and since he has worked in global clinical development for several biotech companies, most recently joining Amgen in 2015 to lead the global development of erenumab (human anti-CGRP receptor mAb) for migraine prevention.

Denis Ardid

Head of the Pharmacology Department , Clermont Universit
Denis Ardid

Pr. Denis Ardid is a professor in Pharmacology at the University of Clermont-Ferrand, France. He is the head of an INSERM team “Fundamental and clinical pharmacology of pain” in the UMR 1107 INSERM/UCA NEURO-DOL, specialized in the pharmacology of chronic pain. After a University background in neurosciences, he has obtained a PhD in pharmacology in 1991 working on the mechanism of action of antidepressant drugs in the treatment of neuropathic pain. In the 2000s, his research field moved to the treatment of chronic visceral pain mainly colonic pain. He has developed many preclinical studies focusing on new emerging treatments of colonic hypersensitivity based on new targets (ionic channels) and on microbiota manipulation.

Eric Nisenbaum

Head of Neurophysiology, Eli Lilly & Co
Eric Nisenbaum

Dr. Nisenbaum received his B.S. in Psychology from Indiana University and his Ph.D. in Neuroscience from the University of Pittsburgh where his research focused on the relationship between changes in neurophysiological, neurochemical and behavioral indices in an animal model of Parkinson’s Disease. He subsequently went to the Department of Anatomy and Neurobiology at the University of Tennessee Health Science Center as a postdoctoral research associate and was granted Young Investigator Awards from the National Alliance for Research on Schizophrenia and Depression (NARSAD) and the Tourette Syndrome Association to study the roles of intrinsic ion channels and their modulation by neurotrasmitters in regulating the excitability of neostriatal neurons. In 1995, he received an NIH FIRST award and continued this research as an assistant professor in the Department of Psychology at the University of Connecticut. In 1998, Dr. Nisenbaum joined Eli Lilly where his research has focused on the biophysical mechanisms and functional consequences of allosteric regulation of ionotropic and metabotropic glutamate receptors and voltage-gated ion channels. He has led multiple cross-functional discovery efforts for glutamate receptor modulators as novel therapies for chronic pain, migraine, cognitive deficits in schizophrenia and neurodegeneration in Parkinson’s Disease. These efforts have contributed to the advancement of several promising drug candidates to the clinic.

Gordon Munro

Senior Scientist, Danish Headache Centre
Gordon Munro

Gordon Munro is a senior scientist at the Danish Headache Center in Copenhagen. A transition from academic research in opioids/neuroendocrinology into pain drug discovery started at NeuroSearch in 2001 and continued at Lundbeck, where pain activities focused primarily on developing modulators of ion channels as novel analgesics. A strong emphasis on animal pain models and behavioral pharmacology has contributed to the publication of 70 peer-reviewed articles, numerous patents and the clinical development of 4 pain-related compounds. He is also associated with the Danish biotech Hoba Therapeutics who are currently developing a novel neurotrophic protein for the treatment of neuropathic pain.

Iain Chessell

VP & Head, IMED Neuroscience , AstraZeneca
Iain Chessell

Dr. Iain Chessell is the Head of the Neuroscience Innovative medicines unit at AstraZeneca, based in Cambridge UK, leading a cross-functional team dedicated to discovery and clinical development of the neuroscience portfolio.Dr. Chessell joined the AstraZeneca (AZ) subsidiary, MedImmune, in November 2008 as vice president, Research, with the intent of initiating neuroscience R&D at MedImmune. After building a portfolio in analgesia and neurodegeneration, in 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE) and subsequently head of the AstraZeneca neuroscience innovative medicines unit. Dr Chessell also serves on the AstraZeneca IMED leadership team which has responsibility for running the AZ’s discovery and early development organisation. Prior to joining AZ, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs for analgesia. Previously, he was global head of pain R&D for GlaxoSmithKline, where he delivered a portfolio of clinical candidates, and was involved in 19 clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 95 peer reviewed publications. Dr. Chessell received his bachelor’s degree in pharmacology from University College London, and received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.

Jean Deregnaucourt

Scientific Director, Innopain
Jean Deregnaucourt

D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at UCLA, was until recently Exec VP Bus Dev at Pasteur Institute after being CEO of the Medicen Paris Region Biocluster. His previous positions were VP Project Management, then VP Chemical and Pharm Dev at Rhone Poulenc Rorer (1990-1998) and later, President of the Pierre Fabre Laboratories R&D (1998-2003). He contributed to the international developments and worldwide registrations of a dozen of products among them two blockbusters, Clexane and Taxotere. Very recently, FDA approved Fetzimab an antidepressor, he patented a few years ago. Since 2016, Jean is now Chief Scientific Director at Innopain.

Kerrie Brady

Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
Kerrie Brady

Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

Lisa Broad

Senior Research Advisor , Eli Lilly and Company
Lisa Broad

Lisa Broad, Ph.D. is a Senior Research Advisor within the Neuroscience division at Eli Lilly and Company, based at Lilly’s European Headquarters near London. Dr. Broad heads up a pre-clinical Neurophysiology group working on Pain/Migraine and Neurodegeneration. Prior to joining Lilly in 2000, Dr. Broad completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge. Dr. Broad received her doctorate from the University of Cambridge in 1997.

Mark Field

Senior Vice President, Head Innovation Unit Pain, Grunenthal GmbH
Mark Field

Michael Scherz

Founder & CEO, Metys Pharmaceuticals
Michael Scherz

Mikhail Kalinichev

Director, in vivo Neurology, Ipsen
Mikhail Kalinichev

Dr. Mikhail Kalinichev received his PhD in Behavioral Neuroscience from Rutgers University (USA) in 1998. From 1998-2002 he was a Post-doctoral fellow at the Department of Pharmacology, Emory University School of Medicine in Atlanta (USA). In 2002 he moved to Europe to join the Psychiatry Center of Excellence at GlaxoSmithKline in Harlow, UK to lead the in vivo activities of several drug discovery programs in the area of schizophrenia, bipolar disorders and epilepsy. In 2009 Dr. Kalinichev joined Addex Therapeutics in Geneva, Switzerland to lead the in vivo pharmacology research, while also playing part in setting therapeutic strategy, business development and external research collaborations and partnerships for the company. From 2014-2015 Dr. Kalinichev was working at Lundbeck pharmaceuticals in Copenhagen, Denmark, leading the in vivo pharmacology research in the area of cognitive impairment associated with psychiatric and neurodegenerative disorders and pain. Currently Dr. Kalinichev is a Director, in vivo Neurology at Ipsen Innovation in France, where he leads the in vivo pharmacology research in the area of botulinum neurotoxins. Dr. Mikhail Kalinichev received numerous honors and awards, including The GlaxoSmithKline Exceptional Science Award and The Vernalis Prize of the British Association for Psychopharmacology. He has published over 40 articles and book chapters in the area of drug discovery in psychiatry and neurology.

Neil Singla

Founder & Chief Scientific Officer, Lotus Clinical Research, Llc
Neil Singla

Neil Singla, MD, Founder & Chief Scientific Officer, Lotus Clinical Research, LLC - Dr. Neil Singla is a nationally recognized key opinion leader in analgesic protocol design and implementation. He has published extensively and is a frequent lecturer for physicians, pharmaceutical companies and medical research institutes throughout the country. For the past several years, the main focus of Dr. Singla's academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint clinical trials can be minimized. He has developed novel techniques for patient education designed to minimize variability, reduce placebo response and increase effect size. Dr. Singla also serves as Chairman of the Clinical Trials Special Interest Group at both the American Pain Society and the International Association for the Study of Pain.

Randall Stevens

Chief Medical Officer, Centrexion Therapeutics Corp.
Randall Stevens

Randall Stevens, M.D. joined Centrexion Therapeutics as the Chief Medical Officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the Corporate Vice President, Head of Inflammation and Immunology Clinical Development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he is Clinical Professor of Medicine at Robert Wood Johnson School of Medicine and on the faculty since 1987.

Sigal Meilin

Chief Scientific Officer, MD Biosciences
Sigal Meilin

Sigal Meilin’s passion over 25 years has been in the understanding of neuro-degeneration and pain processes. Her research focus has been on exploring and creating true models of pain including translational models in pigs which closely mimic and forecast drug activity in humans. The MD Biosciences Innovalora laboratories, under the scientific leadership of Sigal Meilin, have become leaders in the discovery and validation of novel pathways and new candidate drugs. Sigal Meilin holds a PhD from Bar Ilan University in Tel Aviv, Israel where she also continued her research involving multi-parametric monitoring of the living brain under oxygen stress and the cross talk between the immune system and the neuronal system in neurodegenerative disease. She was the leader of the pharmacology department of Pharmos, Ltd, prior to joining MD Biosciences in 2006.

William Schmidt

Vice President, Clinical Development , ViroMed
William Schmidt

Dr. Schmidt has more than 30 years of experience in pain medicine pharmaceutical development. He is President of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs to pharma and biotech companies worldwide, and simultaneously part-time VP of Clinical Development for ViroMed Co., Ltd. (Seoul, South Korea). In previous assignments, Dr. Schmidt was a key member of teams leading to the development and regulatory approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist, Acelex® (polmacoxib), a dual-acting COX-2 and carbonic anhydrase inhibitor, nalbuphine (Nubain®), naltrexone (ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco.

Yanina Flossbach

Associate Medical Director Neuroscience , Novartis Pharmaceuticals
Yanina Flossbach

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Opening Remarks and Introdcutions

Joanne Taylor

Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group

Elisavet Primpidou

Elisavet Primpidou, Associate Vice President, Prescient Healthcare Group

clock

9:10

Overview of the current pain therapeutics landscape

  • Current market
  • Drugs in development
  • Regulatory challenges
  • Current value propositions
     
  • Joanne Taylor

    Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group

    Elisavet Primpidou

    Elisavet Primpidou, Associate Vice President, Prescient Healthcare Group

    clock

    9:50

    How is the pain therapeutics landscape likely to change in the next 3-5 years?

  • Novel mechanisms
  • Disruptive technologies
  • Regulatory changes
  • Future access requirements
  • Joanne Taylor

    Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group

    Elisavet Primpidou

    Elisavet Primpidou, Associate Vice President, Prescient Healthcare Group

    clock

    10:30

    Morning Coffee

    clock

    11:00

    How can drugs in development successfully differentiate in the future pain therapeutics market?

  • Critical success factors in the future market
  • Future stakeholders
  • Differentiated future value propositions
  • Joanne Taylor

    Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group

    Elisavet Primpidou

    Elisavet Primpidou, Associate Vice President, Prescient Healthcare Group

    clock

    11:40

    Practical steps toward future success

  • Open discussion on practical steps to plan for success in the future pain therapeutics market
  • Joanne Taylor

    Joanne Taylor, VP, Head of Neuroscience, Prescient Healthcare Group

    Elisavet Primpidou

    Elisavet Primpidou, Associate Vice President, Prescient Healthcare Group

    clock

    12:20

    Closing Remarks

    clock

    12:30

    End of Workshop

    clock

    13:30

    Registration & Coffee

    clock

    14:00

    Opening Remarks and Introductions

    Simon Ruini

    Simon Ruini, Director, Pharma Design Ltd.

    clock

    14:10

    Guidelines and Regulatory Aspects regarding Clinical Development of products intended for the treatment of pain

    Simon Ruini

    Simon Ruini, Director, Pharma Design Ltd.

  • Comparison of guidelines and regulatory aspects in E.U and U.S.A
  • Definitions and indications
  • EMA and FDA Guidance
  • Claims and labelling
  • Limitations of established pain classifications
  • clock

    14:50

    Clinical Study design for the development of products intended for the treatment of pain.

    Simon Ruini

    Simon Ruini, Director, Pharma Design Ltd.

  • Clinical endpoints
  • Choise of comparators
  • Patient Populations
  • Outcome measures
  • Unmet needs
  • clock

    15:30

    Afternoon Tea

    clock

    16:00

    Recent License Approvals in E.U. and U.S.A.

    Simon Ruini

    Simon Ruini, Director, Pharma Design Ltd.

  • Recent EMA and FDA License aprovals
  • What has convinced Regulators?
  • Whathas not convinced regulators?
  • clock

    16:40

    Inflammatory, Chronic and Post-operative pain treatments - Market opportunities in E.U. and U.S.A.

    Simon Ruini

    Simon Ruini, Director, Pharma Design Ltd.

  • Patient Journeys
  • Mrket objectives
  • Prescribing trends in EU and USA
  • clock

    17:20

    Closing Remarks

    clock

    17:30

    End of Workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    William Schmidt, Vice President, Clinical Development , ViroMed

    clock

    9:10

    Finding targets and using animal models appropriately for pain therapeutics

    Lisa Broad, Senior Research Advisor , Eli Lilly and Company

  • Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
  • Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
  • This presentation will address these questions considering various examples.
  •  

    clock

    9:45

    Drug discovery approaches in neuropathic pain and migraine – apples and oranges or lemons and limes?

    Gordon Munro, Senior Scientist, Danish Headache Centre

  • Therapeutics target distinct facets of disease pathophysiology in neuropathic pain and migraine
  • Shared neurobiological mechanisms in neuropathic pain and migraine
  • Limitations to drug development –animal models and/or patient populations
  • Harmonizing knowledge gained from neuropathic pain research and development with migraine drug discovery
     
  • clock

    10:20

    Morning Coffee

    clock

    10:55

    Dissociation of Responses to Heat and Mechanical Stimuli in a Rodent Model of Rett Syndrome

    Sigal Meilin, Chief Scientific Officer, MD Biosciences

    clock

    11:30

    Second Networking Break

    clock

    11:45

    KEYNOTE ADDRESS: Abdominoplasty as a Novel Analgesic Model for Acute Soft Tissue Pain

    Neil Singla, Founder & Chief Scientific Officer, Lotus Clinical Research, Llc

    clock

    12:45

    Networking Lunch

    clock

    13:45

    Updates on the Therapeutic Application of Botulinum Neurotoxin in Pain: A pre-clinical approach

    Mikhail Kalinichev, Director, in vivo Neurology, Ipsen

    •  While the therapeutic application of botulinum neurotoxin in pain field has grown rapidly during the last decades, the growth has been led primarily by observations and studies performed in the clinic 
    •  Testing botulinum neurotoxin in pre-clinical models of pain can provide an opportunity for systematic evaluation of treatment variables and subsequent improvements in clinical study design
    • Pre-clinical experiments can also help further our understanding of the mechanisms mediating therapeutic efficacy of neurotoxin in pain and in designing a range of modified neurotoxin molecules with enhanced therapeutic profiles
    clock

    14:25

    VM202, a DNA-based Potential Disease-Modifying Treatment for Painful Diabetic Neuropathy

    William Schmidt, Vice President, Clinical Development , ViroMed

  • VM202 is a naked plasmid DNA vector engineered to express two isoforms of human hepatocyte growth factor (HGF).
  • In an ongoing Phase 3 clinical study, VM202 (8 mg/leg) or Placebo is administered i.m. to the calf muscle of each leg in a defined multi-injection pattern on Days 0 and 14 and again on Days 90 and 104.
  • Phase I/II and separate Phase 2 results show robust reductions in foot pain (p<0.05 vs. baseline) and a trend in improved sensory function through 9-12 months after initial treatment in subjects receiving VM202.
  • Pain relieving effects were more pronounced in patients who are not taking Lyrica (pregabalin) and/or Neurontin (gabapentin).
  • VM202 demonstrated an excellent safety profile in Phase I/II and Phase 2 clinical studies.
  • clock

    15:00

    Zilretta: Development of an extended release intra-articular therapeutic for osteoarthritis

    Becca Senter, Principal Scientist, Pharmacology, Flexion Therapeutics

  • Zilretta microsphere technology – how does it work?
  • The challenges of developing an extended release product
  • Summary of pre-clinical data
  • Summary of clinical studies
  • Case study examples
     
  • clock

    15:35

    Afternoon Tea

    clock

    16:05

    Trial conduct in chronic pain conditions; Pitfalls and challenges

    Yanina Flossbach

    Yanina Flossbach, Associate Medical Director Neuroscience , Novartis Pharmaceuticals

  • Patient reported outcomes in clinical trials in pain
  • Reducing placebo responses
  • Patient recruitment challenges 
  • Data handling and management
  • Other considerations
     
  • clock

    17:20

    Chairman’s Closing Remarks and Close of Day One

    William Schmidt, Vice President, Clinical Development , ViroMed

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Co-chairs' Opening Remarks

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.

    clock

    9:10

    The TREK 1 agonists, a promising way to solve the opioid crisis?

    Denis Ardid, Head of the Pharmacology Department , Clermont Universit

  • An exemple of TREK 1 agonists: the substituted acrilyc acid derivatives
  • In vitro and in vivo pharmacological profile
  • Challenges and promises for the future
     
  • clock

    9:45

    CNTX-6970 a novel CCR2 antagonist with a unique analgesic signature

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.

  • Mechanism of action
  • Unique analgesic signature in preclinical models
  • Using Big Data to identify clinical development targets
  • Findings from Phase 1 clinical studies and next steps
     
  • clock

    10:20

    Morning Coffee

    clock

    10:50

    Selective TARP-dependent AMPA Receptor Antagonists as a Novel Therapy for Chronic Pain

    Eric Nisenbaum, Head of Neurophysiology, Eli Lilly & Co

  • The role of AMPA receptors in synaptic plasticity in pain pathways
  • Expression and functional consequences of Transmembrane AMPA receptor Regulatory Proteins (TARPs)
  • Identification of TARP-dependent AMPA receptor antagonists
  • Evidence for LY3130481 (CERC-611) as a novel analgesic
  • clock

    11:25

    Drugging the un-druggable: P2X4 mAbs as therapeutics for pain

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca

  • Novel approaches to discovery of antibodies to P2X4
  • Functional and electrophysiological characterisation
  • Reaching the CNS – application of novel BBB technologies to access the spinal cord with antibody therapies
  • Efficacy in preclinical models and next steps
     
  • clock

    12:00

    Round table discussion session

  • Why do we fall short in demonstrating the efficacy of novel therapeutic compounds in the lab?
    Iain Chessell

     

  • Opioid drugs – Amid an opioid crisis, do abuse resistant drugs work and are we doing enough to reduce harm from opioids?
    Joseph Stauffer

     

  • How should patient engagement be managed clinical trials for analgesic drugs to reduce the placebo effect and increase the success of clinical trials?
    Randall Stevens

     

  • What can the pain therapeutics industry expect with the ageing population?
    Kerrie Brady

     

  • Why are novel analgesic targets so challenging to find and target effectively with drugs?
    Jenny Laird

     

  • Can stem cells ever replace animal models in preclinical studies? – Benefits and challenges.
    Theo Meert

     

  • Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca

    clock

    12:35

    Networking Lunch

    clock

    13:35

    Big Data for Big Decisions

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.

  • How to best develop a portfolio of novel non-opioid products for pain?
  • Integration of human expertise and artificial intelligence
  • Using metadata to qualify big data output
  • Can Big Data increase technical success for novel pain drug development?
     
  • clock

    14:10

    Development update on Erenumab

    Daniel Mikol, Executive Medicl Director Global Development Neuroscience, Amgen

  • The calcitonin gene-related peptide  (CGRP) pathway is pathophysiologically relevant in migraine
  • Erenumab is an investigational monoclonal antibody targeting the canonical receptor for CGRP
  • In episodic migraine prevention studies, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute headache medications
  • In chronic migraine, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute medications in patients with or without acute medication overuse
     
  • clock

    14:45

    Afternoon Tea

    clock

    15:15

    An industry perspective from Grunenthal

    Mark Field

    Mark Field, Senior Vice President, Head Innovation Unit Pain, Grunenthal GmbH

    clock

    15:55

    Co-chairs' Closing Remarks and Close of Day Two

    clock

    16:00

    End of day networking session


    Principal Scientist, Pharmacology
    Flexion Therapeutics
    Executive Medicl Director Global Development Neuroscience
    Amgen
    Head of the Pharmacology Department
    Clermont Universit
    Head of Neurophysiology
    Eli Lilly & Co
    Senior Scientist
    Danish Headache Centre
    VP & Head, IMED Neuroscience
    AstraZeneca
    Scientific Director
    Innopain
    Chief Business Officer, Executive VP Strategy
    Centrexion Therapeutics Corp.
    Senior Research Advisor
    Eli Lilly and Company
    Senior Vice President, Head Innovation Unit Pain
    Grunenthal GmbH
    Founder & CEO
    Metys Pharmaceuticals
    Director, in vivo Neurology
    Ipsen
    Founder & Chief Scientific Officer
    Lotus Clinical Research, Llc
    Chief Medical Officer
    Centrexion Therapeutics Corp.
    Chief Scientific Officer
    MD Biosciences
    Vice President, Clinical Development
    ViroMed
    Associate Medical Director Neuroscience
    Novartis Pharmaceuticals

    Sponsors and Exhibitors

    Official Media Partner

    Official Publication

    Online Partner

    Supporters

    [Interview] - W. Schmidt, ViroMed

    Download

    [Attendee list] - Pain Therapeutics 2018

    Download

    [Programme] - Main Conference

    Download

    [Speaker Line-up]

    Download

    [Workshop B] - Programme

    Download

    [Workshop A] - Programme

    Download

    [Interview] - Randall Stevens, Centrexion Therapeutics

    Download

    [Interview] - Kerrie Brady, Centrexion Therapeutics

    Download

    [Interview] - Lotus Clinical Research

    Download

    [Infographics] - Pain Therapeutics Conference

    Download

    WELCOME LETTER FROM THE CHAIRS

    Download

    Sponsors and Exhibitors


    Lotus Clinical Research

    Sponsors and Exhibitors
    http://www.LotusCR.com

    Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments, focused on improving the scientific accuracy of analgesic programs. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain, providing scientific leadership at every step of the development process.


    MD Biosciences

    Sponsors and Exhibitors
    https://www.mdbneuro.com

    MD Biosciences Neuro is a preclinical and translational contract research organization (CRO) offering services for drug development in the field of neurology and pain research. We understand that finding a trust-worthy preclinical partner is a top priority for drug developers and believe that you should have confidence in the partner you choose. That's why we are dedicated to providing each client valued expertise and advice, experience for flawless execution, and flexibility to meet the needs of rapidly changing requirements.

    With a presence in the innovation hubs of Cambridge, Massachusetts and with state of the art laboratories in Israel, our team is dedicated to building collaborative programs and creating lasting partnerships in the biotechnology community.



    Premier Research

    Sponsors and Exhibitors
    http://www.premier-research.com

    Premier Research is a leading clinical development service provider that helps highly innovative biotech, specialty pharma, and medical device companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatrics, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.

    Media Partners


    Pain News

    Official Media Partner
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.


    The British Journal of Pain

    Official Media Partner
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.

    Media Partners


    ACNR

    Official Publication
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.

    Media Partners


    Centre for Human Drug Research

    Online Partner
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.


    Media Partners


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    MedTube

    Supporters
    https://medtube.net/



    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    EIN Presswire

    Supporters
    http://www.einpresswire.com/free

    EIN Presswire has a distribution "foot-print" that includes millions of users of our EIN Newsdesk media monitoring services. We also maintain one of the world's leading media directories providing us with up-to-date contacts for media in every country and U.S. state. Further distribution is achieved via RSS, email, partner websites, and social media. We are both a destination (EIN Newsdesk) and a distributor (EIN Presswire) for news. In one place you can distribute your news to the targeted audiences you select and monitor news on that topic published by thousands of worldwide sources. For more information or to try us FREE, please visit www.einpresswire.com/free


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Samedan

    Supporters
    http://www.samedanltd.com/magazine/13.

    International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.